Compare VERX & LMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VERX | LMAT |
|---|---|---|
| Founded | 1978 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.1B |
| IPO Year | 2020 | 2006 |
| Metric | VERX | LMAT |
|---|---|---|
| Price | $12.94 | $101.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 5 |
| Target Price | $24.25 | ★ $105.80 |
| AVG Volume (30 Days) | ★ 1.8M | 348.8K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 0.93% |
| EPS Growth | N/A | ★ 30.57 |
| EPS | N/A | ★ 0.68 |
| Revenue | ★ $748,444,000.00 | $249,602,000.00 |
| Revenue This Year | $12.78 | $14.21 |
| Revenue Next Year | $11.61 | $8.88 |
| P/E Ratio | $302.25 | ★ $151.29 |
| Revenue Growth | 12.25 | ★ 13.53 |
| 52 Week Low | $10.21 | $79.01 |
| 52 Week High | $36.75 | $118.01 |
| Indicator | VERX | LMAT |
|---|---|---|
| Relative Strength Index (RSI) | 57.04 | 64.85 |
| Support Level | $12.41 | $82.65 |
| Resistance Level | $13.73 | $114.38 |
| Average True Range (ATR) | 0.62 | 3.07 |
| MACD | 0.15 | 1.45 |
| Stochastic Oscillator | 91.03 | 98.62 |
Vertex Inc is a provider of tax technology and services. Its software, content, and services help customers stay in compliance with indirect taxes that occur in taxing jurisdictions all over the world. It provides cloud-based and on-premise solutions to specific industries for every line of tax, including income, sales, consumer use, value-added, and payroll. The company offers solutions such as tax determination, Tax Data Management, document management, and compliance and reporting, among others. The company derives revenue from software subscriptions.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.